Global Molecular Pharming Market Growth (Status and Outlook) 2023-2029

Global Molecular Pharming Market Growth (Status and Outlook) 2023-2029

The global Molecular Pharming market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Molecular Pharming is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Molecular Pharming is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Molecular Pharming is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Molecular Pharming players cover Medicago Inc, Meristem Therapeutics S.A. (Ventria Bioscience), Miruku, Moolec Science Limited, mozza, Nobell Foods, Agrenvec S.L, Bright Biotech and Core Biogenesis, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

Molecular pharming, also known as biopharming, is a technology that involves the use of genetically modified plants to produce pharmaceuticals or industrial chemicals. This approach relies on the ability of plants to serve as bioreactors for the production of proteins and other complex molecules.

To produce a desired protein, the gene encoding the protein is first inserted into the plant genome. The plant is then grown under controlled conditions, and the protein is harvested from the plant tissue. The protein can then be purified and used for a variety of applications, including drug development, vaccines, and enzyme replacement therapies.

Molecular pharming has several advantages over traditional methods of protein production. Plants are relatively easy to grow and require minimal processing, which can result in lower production costs. Additionally, plant-based production systems are considered to be safer than those that use animal cells or bacteria, as plants are less likely to transmit viruses or other contaminants.

Despite its potential benefits, molecular pharming also has some limitations and challenges. One of the main challenges is ensuring that the plant-produced proteins are properly folded and functional, which can be influenced by factors such as post-translational modifications, environmental conditions, and the choice of plant species. Additionally, there are regulatory and ethical considerations associated with using genetically modified plants for pharmaceutical production.

LPI (LP Information)' newest research report, the “Molecular Pharming Industry Forecast” looks at past sales and reviews total world Molecular Pharming sales in 2022, providing a comprehensive analysis by region and market sector of projected Molecular Pharming sales for 2023 through 2029. With Molecular Pharming sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Molecular Pharming industry.

This Insight Report provides a comprehensive analysis of the global Molecular Pharming landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Molecular Pharming portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Molecular Pharming market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Molecular Pharming and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Molecular Pharming.

This report presents a comprehensive overview, market shares, and growth opportunities of Molecular Pharming market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Gene Gun
Agroinfiltration
Electroporation
Agrobacterium-Mediated Gene Transfer

Segmentation by application
Recombinant Antibodies
Hormones, Vaccines
Industrial Enzymes
Proteins & Protein-Based Materials
Technical Reagents
Nutritional Products

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Medicago Inc
Meristem Therapeutics S.A. (Ventria Bioscience)
Miruku
Moolec Science Limited
mozza
Nobell Foods
Agrenvec S.L
Bright Biotech
Core Biogenesis
Diamante SRL
Leaf Systems International Limited
ORF Genetics
Pfizer, Inc.
ProdiGene Inc
Protalix Biotherapeutics, Inc
Tiamat Sciences

Please note: The report will take approximately 2 business days to prepare and deliver.